Skip to main content
SpringerLink
Log in

Criteria to Reevaluate Anti-drug Antibody Assay Cut Point Suitability in the Target Population

  • Brief/Technical Note
  • Published:
The AAPS Journal Aims and scope Submit manuscript

Abstract

After tier 1 and 2 cut points for anti-drug antibody (ADA) assays are derived during pre-study assay validation in a population, there is a need to verify the continued appropriateness of the previously derived cut points during sample analysis in the same or different populations, per FDA guidance (US HHS, FDA, CDER, CBER, 2019). Proper sample size–dependent criteria with statistical underpinning were derived and presented in this technical note to aid in assessing the appropriateness of tier 1 and tier 2 cut points, respectively.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

References

  1. US HHS, FDA, CDER, CBER Immunogenicity testing of therapeutic protein products—developing and validating assays for anti-drug antibody detection, Guidance for Industry, January 2019, page 28. https://www.fda.gov/media/119788/download

  2. Devanarayan V, Smith WC, Brunelle RL, Seger ME, Krug K, Bowsher RR. Recommendations for systematic statistical computation of immunogenicity cut points. AAPS J. 2017;19:1487–98. https://doi.org/10.1208/s12248-017-0107-3.

    Article  CAS  PubMed  Google Scholar 

  3. Amaravadi L, et al. White paper on recent issues in bioanalysis: focus on new technologies and biomarkers (part 3--LBA, biomarkers and immunogenicity). Bioanalysis. 2015;7(24):3107–24. https://doi.org/10.4155/bio.15.226.

    Article  CAS  PubMed  Google Scholar 

  4. Song S, Yang L, Trepicchio WL, Wyant T. Understanding the supersensitive anti-drug antibody assay: unexpected high anti-drug antibody incidence and its clinical relevance. J Immunol Res. 2016. https://doi.org/10.1155/2016/3072586.

Download references

Author information

Authors and Affiliations

  1. Worldwide Research Development and Medical, Pfizer Inc., 500 Arcola Rd, Collegeville, Pennsylvania, 19426, USA

    Charles Y. Tan, Gregory S Steeno, Zhiping You, Puneet Gaitonde, Chun-Hua Cai, John Kamerud, Boris Gorovits & Daniel J. Baltrukonis

Authors
  1. Charles Y. Tan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gregory S Steeno
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Zhiping You
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Puneet Gaitonde
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Chun-Hua Cai
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. John Kamerud
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Boris Gorovits
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Daniel J. Baltrukonis
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Charles Y. Tan.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tan, C.Y., Steeno, G.S., You, Z. et al. Criteria to Reevaluate Anti-drug Antibody Assay Cut Point Suitability in the Target Population. AAPS J 22, 19 (2020). https://doi.org/10.1208/s12248-019-0400-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1208/s12248-019-0400-4

KEY WORDS

Search

Navigation